BMYClinical Trials•businesswire•
Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis
Sentiment:Positive (80)
Summary
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #EULAR--BMS Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 11, 2025 by businesswire